Chandan Healthcare Limited Q2 EBITDA rises 54.79%, margin 37.26%
Key highlights
- Chandan’s Q2 FY27 standalone EBITDA rose 54.79% year on year to Rs 22.12 crore.
- Chandan’s Q2 FY27 EBITDA margin increased 241 basis points to 37.26% from 34.85%.
- Chandan’s Q2 FY27 PAT of Rs 18.61 crore included a Rs 10.23 crore one-time gain, net of tax.
- Chandan’s franchise network reached 685 centres at 30 September 2026, up from 264 at 30 June 2026.
powered by IRIS

Chandan Healthcare Limited reported standalone Q2 FY27 EBITDA of Rs 22.12 crore, up 54.79% year on year, and expanded its EBITDA margin by 241 basis points to 37.26%. Chandan’s reported profit after tax of Rs 18.61 crore included a Rs 10.23 crore one-time exceptional gain, net of tax, from the sale of its Chandan Pharmacy Limited investment.
Know Chandan Healthcare inside out
Results, valuation, peers and who's buying, in one view.
How did Chandan’s Q2 FY27 operating performance change?
Chandan’s operating performance improved in Q2 FY27 as revenue rose 45.04% year on year to Rs 57.94 crore from Rs 39.95 crore, while total income increased 44.78% to Rs 59.36 crore from Rs 41.00 crore. EBITDA, or earnings before interest, tax, depreciation and amortisation, increased faster than total income, rising from Rs 14.29 crore to Rs 22.12 crore.
The higher rate of EBITDA growth lifted Chandan’s EBITDA margin to 37.26% from 34.85% in Q2 FY26, a 241-basis-point increase. Total expenditure rose to Rs 37.24 crore from Rs 26.71 crore; Q2 FY27 expenses included Rs 9.05 crore of raw-material costs, Rs 14.35 crore of employee-benefit costs and Rs 13.84 crore of other expenses.
Chandan also recorded sequential growth in Q2 FY27: revenue was 19.06% above Q1 FY27 revenue of Rs 48.67 crore and EBITDA was 21.57% above Rs 18.19 crore. The EBITDA margin rose by 69 basis points from 36.57% in Q1 FY27, so the margin improved both year on year and quarter on quarter.
What drove Chandan’s reported PAT increase?
Chandan’s reported Q2 FY27 profit after tax, or PAT, rose 224.19% to Rs 18.61 crore from Rs 5.74 crore, but it included a Rs 10.23 crore exceptional gain from the pharmacy investment sale. The presentation identifies that gain as net of tax and outside regular operations, meaning the reported PAT comparison includes a non-recurring item.
Profit before tax, or PBT, before the exceptional item rose 63.88% to Rs 12.91 crore from Rs 7.88 crore. Finance costs increased to Rs 4.59 crore from Rs 2.96 crore, depreciation rose to Rs 4.62 crore from Rs 3.44 crore, and tax expense was Rs 4.53 crore compared with Rs 2.14 crore a year earlier.
Chandan’s PAT margin reached 31.35% in Q2 FY27, up 1,735 basis points from 14.00%, compared with a 241-basis-point rise in EBITDA margin. Sequentially, PAT rose from Rs 6.76 crore in Q1 FY27 and PAT margin increased from 13.58%, with the Q2 figure including the exceptional gain.
Management said the Board approved the sale of the entire pharmacy stake in August and completed it during Q2 FY27. Management described pharmacy as a low-margin business with more than 70% of its revenue from business-to-business supply, and said proceeds would be directed towards diagnostic centres.
Got a follow-up? Ask IRIS
How did Chandan perform in H1 FY27?
Chandan’s H1 FY27 revenue rose 41.16% to Rs 106.61 crore from Rs 75.53 crore, while total income increased 40.56% to Rs 109.12 crore. H1 EBITDA grew 66.52% to Rs 40.31 crore from Rs 24.21 crore, outpacing income growth and raising EBITDA margin by 576 basis points to 36.95%.
H1 FY27 PAT rose 256.72% to Rs 25.37 crore from Rs 7.11 crore, including the Rs 10.23 crore exceptional gain recorded in Q2 FY27. PBT before the exceptional item doubled to Rs 22.87 crore from Rs 11.39 crore, while finance costs increased to Rs 8.65 crore and depreciation rose to Rs 8.80 crore.
Chandan’s H1 PAT margin was 23.25%, compared with 9.16% in H1 FY26, a 1,409-basis-point increase that includes the pharmacy-sale gain. The presentation reports these as standalone figures because Chandan Pharmacy Limited was deconsolidated, with prior-year comparisons presented on the same standalone basis.
What could shape Chandan’s next results?
Chandan linked Q2 FY27 diagnostics growth to expansion of its franchise collection network, which rose to 685 centres at 30 September 2026 from 264 centres at 30 June 2026. The 410 additions during Q2 put the network above the 235 centres reported at 31 March 2026.
Management has stated a target of 1,000 franchise centres by the end of FY27 and 3,000 over the following two years. Under the asset-light model, franchise partners bear local infrastructure and operating costs, while Chandan provides diagnostic capability, quality protocols, branding and support; samples are routed to nearby Chandan laboratories or diagnostic centres.
Around 80% of the franchise network was in Uttar Pradesh at 30 September 2026, while management described expansion into newer geographies as the next phase. Chandan also acquired two Ansh Diagnostics & Health Care units in Ghaziabad under a 25 September 2026 agreement, adding pathology and radiology services including computed tomography and magnetic resonance imaging.
Management said it plans to add franchise centres, open owned centres in selected markets, expand work with Jeena Sikho hospitals and clinics, and grow business-to-government operations during the rest of FY27. The presentation also disclosed three 10-year radiology public-private partnership awards in Punjab, alongside awards in Rohtak and NFR Guwahati.
Conclusion
Chandan’s Q2 FY27 results showed revenue growth of 45.04%, EBITDA growth of 54.79% and a 37.26% EBITDA margin, indicating that operating profit increased faster than total income. The 224.19% increase in reported PAT was substantially affected by the Rs 10.23 crore one-time pharmacy-sale gain, which was recorded below EBITDA.
The next disclosed measures to watch are management’s progress towards 1,000 franchise centres by FY27-end, additions to owned diagnostic capacity and utilisation of the expanded collection network. Results will also show how the diagnostics-only business performs after the pharmacy divestment took effect on 1 September 2026, without a further sale gain in the comparison.


